EAM
CMPX icon

Eventide Asset Management’s Compass Therapeutics CMPX Stock Holding History

Eventide Asset Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-935,091
Closed -$4.7M – 153
2022
Q4 		$4.7M Sell
935,091
-165,308
-15% -$659K 0.09% 126
2022
Q3 		$2.51M Buy
+1,100,399
New +$3.05M 0.05% 133

Other funds holding CMPX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Eventide Asset Management's CMPX Position: Q1 2023 in Review

Eventide Asset Management sold out of Compass Therapeutics (CMPX) in Q1 2023, closing a stake of 935,091 shares — an estimated $4.7M sold.

Eventide Asset Management first reported a position in CMPX in Q3 2022 and held it in 2 quarters. The position peaked at $4.7M in Q4 2022. 72 funds tracked by Wall St. Rank hold CMPX as of Q1 2023.

  • Eventide Asset Management reported no remaining Compass Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Eventide Asset Management sold 935,091 Compass Therapeutics shares in Q1 2023, an estimated $4.7M.
  • Eventide Asset Management first reported a position in Compass Therapeutics in Q3 2022 and held it in 2 quarters.
  • Eventide Asset Management's Compass Therapeutics position peaked at $4.7M in Q4 2022.
  • 72 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2023.

Based on Eventide Asset Management's 13F filing for Q1 2023, filed 15 May 2023.